Effect of Vilanterol on Methacholine Challenge Results

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the degree of bronchoprotection provided by the ultra long-acting beta2 agonist vilanterol against methacholine-induced bronchoconstriction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Saskatchewan
• Treatments: Fluticasone; Methacholine Chloride; Xhance

Criteria

Inclusion Criteria:

• men and women aged 18 or older

• stable mild-to-moderate asthma

• baseline methacholine PC20 less than or equal to 8mg/mL

• FEV1 greater than or equal to 65% of predicted

Exclusion Criteria:

• Use of long-acting anticholinergic or long-acting beta2 agonist within 30 days of study

• pregnant or nursing

• diabetes

• hypokalemia

• cardiovascular, prostate, kidney, or urinary retention problems

• lactose-intolerant

• allergy-induced asthma symptoms or upper respiratory tract infection within four weeks of study

• current smokers

• past smokers with smoking history >10 pack years